Higher baseline LTF levels in ES-SCLC patients may predict durable chemoimmunotherapy outcomes, suggesting LTF as a potential biomarker for treatment response. LTF appears to suppress SCLC tumors ...

Key Takeaways SCLC incidence in the US is projected to decline significantly through 2050, continuing a trend from 2000 to 2021.

A new research paper was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine ...

As you mentioned, SCLC is such a recalcitrant disease, so it's exciting to see so many hopeful therapeutic options now available. Imdelltra currently has an accelerated approval in the second line. I ...

Amgen and MediLink Therapeutics have agreed to a research and supply collaboration to develop a combination therapy for extensive-stage small cell lung cancer (ES-SCLC). Suzhou, China-based ...

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a ...